TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR
Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.
Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval
After years of trying to catch up with the competition, Boston Scientific is moving on. The company is no longer seeking approval from the FDA or any other regulatory agencies for these devices, and all global sales have been discontinued.
Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.
Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs
Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.
Medtronic gains a key approval for Evolut TAVR valves
More patients can now undergo redo TAVR with a Medtronic valve than ever before.

CAC scores help predict TAVR mortality

The analysis, published in Radiology, included more than 300 patients who presented with severe aortic stenosis.

‘Making good, better’: Next-gen TAVR techniques and protocols optimize patient care, boost efficiency

Sponsored by Medtronic

Innovation in the transcatheter aortic valve replacement (TAVR) space has upped the ante once again.

AI model evaluates ECG data as well as cardiologists

The team's convolutional neural network was trained on data that is readily available at most facilities.

TAVR outcomes similar after 1 year in low-risk bicuspid, tricuspid aortic stenosis patients

Lead author John Forrest, MD, a cardiologist at Yale School of Medicine, presented the findings at TVT 2021. He noted that it felt great to finally return to in-person conferences after COVID kept people at home for so long.

DOACs outperform VKAs when TAVR patients require oral anticoagulation

Hoping to shed new light on the debate between DOACs and VKAs, researchers in France examined data from more than 24,000 TAVR patients.

AI model predicts diabetes risk using MRI results

The algorithm measures the amount of fat surrounding a person's heart, using that information to create an accurate diabetes risk assessment.

TAVR safe for patients with inflammatory bowel disease

Patients with Crohn’s disease and ulcerative colitis can safely undergo TAVR, researchers at the Cleveland Clinic have confirmed in a new analysis.

Permanent pacemaker implantation before or after TAVR linked to worse outcomes

Researchers tracked more than 49,000 TAVR patients, sharing their findings in Heart Rhythm.

TAVR

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR

Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards

Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs

Medtronic gains a key approval for Evolut TAVR valves